Skip to main content

Trials in Development

This quarter's most recent list of pending trials with general time frames to expected activation. 

Past reports

The planned and recently activated trials lists below is the most up to date and is dynamically generated from our database. 

Planned trials

ALC11

Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy

ALC9

Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)

BR39

LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial

EN12

RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features

HN14

Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC

MA42

No Chemotherapy in Intermediate-risk HR + HER2- Early Breast Cancer Treated with Ribociclib (NoLEEta)

MD1

Combination Therapy with Luspatercept in Lower Risk Myelodysplasia: A Tier 1 myeloMATCH Substudy

More >>

ME18

Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3)

SR8

NeoAdjuvant-only or Peri-operative cemiplimab in high-grade localised soft-tissue SARcoma (NAPStAR)

BI4

Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)

Recently activated

ALC10

Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial

More >>

CE10

VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma

More >>

LYC2

Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)

More >>

PAC5

Lanreotide for the Prevention of Postoperative Pancreatic Fistula

More >>

SC30

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT

More >>

SC32S

Feasibility, Acceptability and Representativeness: Collecting Sociodemographic Data in CCTG Trials

More >>

Patients Stories

New SC32S survey study opens across Canada

New SC32S survey study opens across Canada

A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.

More >>
 
Now open, the SC30 study investigating the role of immunoglobulin and antibiotics on infections in patients with blood cancers

Now open, the SC30 study investigating the role of immunoglobulin and antibiotics on infections in patients with blood cancers

The new SC30 RATIONAL-PT international study is now open in Canada and will compare different approaches to preventing infections in people with blood cancers with low antibody levels. People with blood cancers often develop low levels of antibodies that can lead to an increased chance of developing an infection.

More >>
 
The BR38 trial testing targeted radiotherapy added to immunotherapy to improve outcomes for lung cancer patients.

The BR38 trial is testing targeted radiotherapy added to immunotherapy to improve outcomes for lung cancer patients

The recently opened BR38 clinical trial is exploring whether adding stereotactic body radiotherapy (SBRT) to the current treatment of immunotherapy (with or without chemotherapy) can improve outcomes for patients with metastatic non-small cell lung cancer (NSCLC) and limited disease progression (oligoprogression).

More >>
 
New trial SKC1 is testing the neoadjuvant addition of an immunotherapy drug for advanced skin cancer

New trial SKC1 is testing the neoadjuvant addition of an immunotherapy drug for advanced skin cancer

The SKC1 skin cancer clinical trial is now open to enrollment across Canada. This study aims to determine whether adding an immunotherapy drug prior to the standard surgical treatment for advanced skin cancer can improve patient outcomes. This study addresses a substantial unmet need in this patient population.

More >>